Notes to the Balance Sheet - Summary of Goodwill (Details) - EUR (€)	Dec. 31, 2022	Dec. 31, 2021
Goodwill Acquired [Line Items]
Goodwill	€ 356,239,773	€ 335,574,009
Perpetual growth rate	1.00%
Beta factor	100.00%	90.00%
WACC before Tax	9.80%	8.50%
Discount rate	1.30%
Slonomics Technology [Member] \| Goodwill [member]
Goodwill Acquired [Line Items]
Goodwill	€ 1,600,000
Perpetual growth rate	1.00%
Constellation Pharmaceuticals, Inc. \| Goodwill [member]
Goodwill Acquired [Line Items]
Goodwill	€ 354,600,000
Beta factor	150.00%	170.00%
WACC before Tax	14.70%	14.10%

The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 36
-IssueDate 2022-03-24
-Paragraph 134
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_a&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 36
-IssueDate 2022-03-24
-Paragraph 135
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_135_a&doctype=Standard
-URIDate 2022-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2022-03-24
-Paragraph B67
-Subparagraph d
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B
-URIDate 2022-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 54
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard
-URIDate 2022-03-24

Name:	ifrs-full_Goodwill
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant